다이하이드로다이드제인을 함유하는 피부 미용 조성물
    13.
    发明公开
    다이하이드로다이드제인을 함유하는 피부 미용 조성물 无效
    含有二氢哒嗪的皮肤美容组合物

    公开(公告)号:KR1020120020903A

    公开(公告)日:2012-03-08

    申请号:KR1020100084830

    申请日:2010-08-31

    Abstract: PURPOSE: A composition containing dihydrodaidzein is provided to ensure antiaging and anti-wrinkling and to suppress tyrosinase activity. CONSTITUTION: A composition for skin care contains dihydrodaidzein as an active ingredient. The composition improves skin elasticity or anti-wrinkling and skin whitening. The composition relieves and treats acne, skin trouble, or allergy. The composition is a cosmetic food composition and cosmetic composition.

    Abstract translation: 目的:提供含有二氢黄豆苷元的组合物以确保抗衰老和抗皱纹,并抑制酪氨酸酶活性。 构成:皮肤护理用组合物含有二氢黄豆苷元作为活性成分。 该组合物改善皮肤弹性或抗皱和皮肤美白。 该组合物缓解和治疗痤疮,皮肤麻烦或过敏。 该组合物是化妆品食品组合物和化妆品组合物。

    차나무 뿌리에서 추출한 트리테르페노이드 사포닌을 함유하는 조성물
    16.
    发明公开
    차나무 뿌리에서 추출한 트리테르페노이드 사포닌을 함유하는 조성물 审中-实审
    含有三叶草皂甙的组合物提取物

    公开(公告)号:KR1020130108853A

    公开(公告)日:2013-10-07

    申请号:KR1020120030643

    申请日:2012-03-26

    Abstract: PURPOSE: A composition containing triterpenoid saponin extracted from a methanol extract of Camellia sinensis roots is provided to effectively prevent or treat diabetes, obesity, and hypertension and to be used in food and medical fields. CONSTITUTION: A composition for preventing and treating diabetes contains 0.01-20 wt% of triterpenoid saponin extracted from a methanol extract of Camellia sinensis roots as an active ingredient. Triterpenoid saponin is denoted by chemical formulas 1-10. The composition is a pharmaceutical composition and a health food composition. [Reference numerals] (AA) Green tea ponin R1; (BB) Green tea ponin R2; (CC) Green tea ponin R3; (DD) Green tea ponin R4; (EE) Green tea ponin R5; (FF) Green tea ponin R6; (GG) Green tea ponin R7; (HH) Green tea ponin R8; (II) Green tea ponin R9; (JJ) Green tea ponin R10

    Abstract translation: 目的:提供从山茶根的甲醇提取物中提取的三萜皂苷的组合物,以有效预防或治疗糖尿病,肥胖和高血压,并用于食品和医疗领域。 构成:用于预防和治疗糖尿病的组合物含有0.01-20重量%的从山茶根的甲醇提取物中提取的三萜皂苷作为活性成分。 三萜皂苷由化学式1-10表示。 组合物是药物组合物和保健食品组合物。 [参考数字](AA)绿茶叶素R1; (BB)绿茶茶素R2; (CC)绿茶茶素R3; (DD)绿茶茶素R4; (EE)绿茶色素R5; (FF)绿茶叶素R6; (GG)绿茶叶素R7; (HH)绿茶ponin R8; (二)绿茶色素R9; (JJ)绿茶叶素R10

    필발 열수 추출물을 함유하는 비만 억제용 제제
    17.
    发明公开
    필발 열수 추출물을 함유하는 비만 억제용 제제 审中-实审
    用于抑制包含管道长管的热水提取的成分的代理

    公开(公告)号:KR1020130103882A

    公开(公告)日:2013-09-25

    申请号:KR1020120024869

    申请日:2012-03-12

    Abstract: PURPOSE: An antiobesity agent containing a hot water extract of Piper longum L. is provided to promote lipolysis of subcutaneous adipocytes and to suppress fat accumulation in the subcutaneous adipocytes, thereby preventing or suppressing obesity. CONSTITUTION: An antiobesity agent contains 1-80 wt% of a hot water extract of Piper longum L. as an active ingredient. The extract promotes the decomposition of subcutaneous fat. The obesity is caused by lipid intake. The hot water used for preparing the extract is water of 80-120°C. [Reference numerals] (AA) Degree of fat breakdown (comparing to negative control group); (BB) Hot water 10; (CC) Hot water 50; (DD) Hot water 100; (EE) Alcohol 10; (FF) Alcohol 50; (GG) Alcohol 100

    Abstract translation: 目的:提供含有琵琶龙肝的热水提取物的抗肥胖剂,以促进皮下脂肪细胞的脂肪分解,并抑制皮下脂肪细胞中的脂肪蓄积,从而预防或抑制肥胖。 构成:抗肥胖剂含有1-80重量%的琵琶龙虾热水提取物作为活性成分。 提取物促进皮下脂肪的分解。 肥胖是由脂质摄入引起的。 用于制备提取物的热水为80-120℃的水。 (AA)脂肪分解程度(与阴性对照组相比); (BB)热水10; (CC)热水50; (DD)热水100; (EE)醇10; (FF)酒精50; (GG)酒精100

    시링가레시놀을 포함하는 대사 이상증 개선용 조성물
    18.
    发明公开
    시링가레시놀을 포함하는 대사 이상증 개선용 조성물 审中-实审
    用于改善包含SYRINGARESINOL的代谢紊乱的组合物

    公开(公告)号:KR1020130044707A

    公开(公告)日:2013-05-03

    申请号:KR1020110108904

    申请日:2011-10-24

    Abstract: PURPOSE: A composition containing syringaresinol is provided to suppress fatty acid synthesis, to promote fatty acid oxidation, to enhance PGC 1 expression, and to prevent and treat obesity and hyperlipidemia. CONSTITUTION: A composition for preventing or treating dysbolism contains 1-80 wt% of syringaresinol as an active ingredient. Dysbolism includes disorders of carbohydrate metabolism or lipid metabolism, selected from the group consisting of obesity, type 2 diabetes, hyperlipidemia, and fatty liver. Syringaresinol is contained in extracts which is prepared using one or more selected among linseed, Phellodendron amurense Ruprecht, Acanthopanax senticosus, sesame seeds, and ginseng fruits. [Reference numerals] (AA) mRNA expression of relative SIRT 1; (BB) Fat cell; (CC) Liver cell; (DD) Muscle cell

    Abstract translation: 目的:提供含有丁香胺的组合物,以抑制脂肪酸合成,促进脂肪酸氧化,增强PGC 1表达,并预防和治疗肥胖和高脂血症。 构成:用于预防或治疗dysbolism的组合物含有1-80重量%的作为活性成分的丁香胺。 嗜睡症包括选自肥胖症,2型糖尿病,高脂血症和脂肪肝的碳水化合物代谢或脂质代谢紊乱。 提取物中含有辛伐他汀,该提取物使用亚麻籽,黄柏,麻黄,芝麻,人参果实中的一种或多种进行制备。 (AA)相对于SIRT1的mRNA表达; (BB)脂肪细胞; (CC)肝细胞; (DD)肌肉细胞

Patent Agency Ranking